NLRP3 Inflammasome Activation and Atherogenic Lipid Profile in Hemodialysis Patients
Ther Apher Dial. 2026 May 17. doi: 10.1002/1744-9987.70158. Online ahead of print.ABSTRACTBACKGROUND AND AIMS: End-stage renal disease (ESRD) patients who undergo hemodialysis treatment experience accelerated atherosclerosis development, which results from two main causes: atherogenic dyslipidemia a

